Market Analysis
Why Is Moderna Stock Moving Today? Europe Clears Moderna’s Dual Vaccine
Moderna shares swung in early trading after European regulators backed its combination flu-COVID vaccine.
Total Stories
13
News
mRNA
Section
mRNA
Market Analysis
Why Is Moderna (MRNA) Stock Rising Today? $2.25B Patent Settlement
Moderna stock is rising after the company agreed to pay up to $2.25 billion to settle a patent dispute over technology used in its COVID-19 vaccine.
Market Analysis
Why Is Moderna (MRNA) Stock Down Premarket? FDA Rejects Flu Vaccine Filing
Moderna stock dropped over 9% in premarket trading after the FDA refused to review its mRNA-based flu vaccine, citing inadequate study design.
Market Analysis
Why Is Moderna (MRNA) Stock Up Today: Merck Partnered Vaccine Cuts Recurrence Risk
Moderna stock rose over 7% after the company and Merck said their personalized melanoma vaccine kept working at five years, cutting recurrence or death risk by…
Market Analysis
Moderna Stock Drops as FDA Signals New Restrictions on Vaccine Approvals
Moderna shares fell over 4% after the FDA signaled stricter vaccine approval rules, raising concerns about potential delays for new vaccines.
Market Analysis
Why is Moderna’s Stock Gaining in Premarket Trading Today?
Moderna stock jumped in premarket trading after the FDA granted limited approval for mNEXSPIKE, a new COVID-19 vaccine.
Market Analysis
Trump Admin. Reconsiders $590M Funding for Moderna’s Bird Flu Vaccine
The Trump administration is reconsidering a $590 million contract with Moderna for bird flu vaccine development.
Market Analysis
Moderna Cuts 2025 Sales Forecast Amid Low Vaccine Demand, Stock Plummets
Moderna has lowered its 2025 sales forecast due to decreased demand for its Covid and RSV vaccines.
Market Analysis
Moderna Slashes R&D Budget, Stock Plummets Amid Profitability Concerns
Moderna announced plans to slash its R&D budget by $1.1 billion by 2027.
Market Analysis
Stocks to Watch Today: MRNA, META, and AMAT
Meta Platforms surged on strong earnings and AI progress, while Moderna plummeted after slashing its sales outlook and Applied Materials saw its stock drop after being…
Market Analysis
Stocks to Watch Today: TSLA, RIVN, and Moderna
In a volatile trading day, Tesla and Rivian stocks surged while Moderna shares dipped following disappointing vaccine efficacy data.
Earnings
Moderna’s (MRNA) Unexpected $217 Million Profit Marks a Surprising Q4 Achievement
Moderna Inc. surpassed expectations in Q4 with a revenue of $2.8 billion and a GAAP net income of $217 million.
Best Stocks
Is Pfizer Still a Buy After its CEO Sells Almost $6 Million in Stock?
After long media bombardment primed the public for a COVID-19 vaccine, some Big Pharma CEOs don't seem as enthusiastic.